The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- Risk based approach to Post Market Clinical Follow up (PMCF)
- Questions & Answers on the impact of Mutual Recognition Agreement (MRA) between the European Union and the United States
- Digital label for authorised representative and importer
- MANUAL PARA REGULARIZAÇÃO DE EQUIPAMENTO MÉDICO E SOFTWARE COMO DISPOSITIVO MÉDICO NA ANVISA
- How to Prepare a PreRequest for Designation (Pre-RFD) . FDA Guidance for Industry
- Formação exclusiva Formiventos CTD MODULO 3: “Evento de alta qualidade que permitiu grande interação entre todos os participantes. “
- PREÇOS 2025: “Muito interessante e enriquecedora”
- GUIDANCE DOCUMENT Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications